首页> 外文期刊>Senologie: Zeitschrift fuer Mammadiagnostik und -therapie >Restricted Axillary Staging In Clinically and Sonographically Node-Negatiwe Early Inwasiwe Breast Cancer (cfiT1-2) in the Context of Breast Conserwing Therapys First Results Following Commencement of the Intergroup-Sentlnel-Mlarnma (INSEMA) Trial
【24h】

Restricted Axillary Staging In Clinically and Sonographically Node-Negatiwe Early Inwasiwe Breast Cancer (cfiT1-2) in the Context of Breast Conserwing Therapys First Results Following Commencement of the Intergroup-Sentlnel-Mlarnma (INSEMA) Trial

机译:在临床和超声癌节点中限制腋生分期,在乳房治疗的背景下,在乳房治疗的背景下首先产生跨组 - Sentlnel-Mlarnma(insema)试验

获取原文
获取原文并翻译 | 示例
           

摘要

Axillary lymph node status remains an important prognostic factor in early breast cancer. It is regarded as an indicator for (neo)adjuvant systemic treatment and postoperative radiotherapy of the regional lymphatics. Commenced in September 2015, the INSEMA trial is investigating whether operative determination of nodal status as part of breast conserving therapy (BCT) for early stage breast cancer (c/iTI -2 c/iNO) can be avoided without reducing oncological safety. After inclusion of 1001 patients there was general acceptance of the complex study design by patients and study doctors so that recruitment for the first randomisation (axillary sentinel lymph node biopsy [SLNB]: yes or no) achieved predicted case numbers. The second randomization however (SLNB alone versus complete axillary dissection when one or two macrometastases are present at SLNB) recruited fewer cases than expected for the following three reasons: a) the 13% rate of one or two macrometastases after SLNB in the INSEMA trial collective was lower than expected; b) around 20 % of patients refused the second randomisation; c) there was delayed inclusion of the Austrian study centres, which only recruited for the second randomisation. Lack of knowledge of nodal status when SLNB is avoided represents a new challenge for the postoperative tumour board, in particular decisions on chemotherapy for luminal-like tumours and irradiation of the lymphatics (exckiding axilla) must be guided by tumour biological parameters. The INSEMA trial does not provide answers to some important questions, e. g. it remains unclear whether patients without SLNB can be offered partial breast irradiation alone in low-risk situations and whether SLNB can also be avoided in patients with stage T1 -2 tumours who have a mastectomy indication.
机译:腋窝淋巴结状态仍然是早期乳腺癌的重要预后因素。它被认为是(Neo)佐剂全身治疗和区域淋巴管术后放射治疗的指标。在2015年9月开始,Insema试验正在调查是否可以避免为早期乳腺癌(C / ITI-2 C / INO)作为乳房保守治疗(BCT)的一部分进行术治疗的节点状况(C / ITI -2 C / INO),而不会降低肿瘤医学安全性。在包含1001名患者之后,患者的复杂研究设计一般接受并研究医生,以便招募第一次随机化(腋窝淋巴结活检[SLNB]:是或否)达到预测的案例数。然而,第二种随机化(单独的SLNB与完全腋窝分析在SLNB时)征收比预期的少于预期的三种原因:a)在Inerema试验中SLNB中的SLNB之后的一两种宏观运动速率的13%速率低于预期; b)大约20%的患者拒绝了第二种随机化; c)延迟纳入奥地利学习中心,只招募了第二个随机化。当避免SLNB时,缺乏节点状况的知识代表了术后肿瘤委员会的新挑战,特别是对腔状肿瘤的化疗的决定,淋巴管(猝倒腋窝)必须被肿瘤生物学参数引导。伊斯马日试验不提供一些重要问题的答案,即G。尚不清楚没有SLNB的患者是否可以在低风险情况下单独提供部分乳房照射,并且在具有乳房切除术指示的阶段T1-2肿瘤患者中也可以避免SLNB。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号